T follicular helper REServoir in AXillary lymph nodes (TRESAX) study

Posted by •
Study type
Summary
Inclusion Criteria
Participation requirements
Status
Observational studyThe TRESAX study aims to better understand the contribution that CD4 T follicular helper cells make to the lymph node HIV reservoir.
  • >18 years
  • HIV+
  • ART start >350 CD4 T cells/ul
  • Viral suppression >3 years
  • Written informed consent
  • [Eligible and scheduled for a seasonal flu vaccine]
HIV+ participants will attend up to 12 study visits where blood will be taken for further analysis. Two visits will also require fine needle lymph node biopsies to be done under ultrasound guidance. Some participants will receive the seasonal flu vaccine. All HIV+ participants will stop taking antiretroviral treatments for up to 28 days.Currently recruiting

Study contact

Dr Mee Ling Munier cmunier@kirby.unsw.edu.au

Maxine Elfis Maxine.elfis@svha.org.au

HIV Cure Community Partnership

Hivcure.com.au is the flagship project of the Australian HIV Cure Community Partnership to promote engagement between HIV cure researchers and people living with HIV. Members include NAPWHA, The Doherty Institute for Infection and Immunity, The Kirby Institute, The Alfred Hospital, Living Positive Victoria and Positive Women Victoria.

Must Read

Scroll to Top